The global sleep aids market is estimated to be valued at USD 77.68 Bn in 2024 and is expected to exhibit a CAGR of 7.6% during the forecast period (2024-2031). The global sleep aids market has been witnessing steady growth in the last few years owing to the increasing prevalence of sleep disorders. Rising stress levels, changing lifestyles, and growing aging population have emerged as major factors fueling insomnia and other sleep disorders. Moreover, growing awareness about the ill-effects of sleep deprivation on health and productivity are prompting a greater number of people to seek treatment. Various sleep medications and devices have flooded the market to help people get adequate rest. With growing health consciousness, more natural products like herbs and supplements are also gaining popularity for sleep promotion. The sleep aids market is expected to further grow at a notable rate in the coming years on the back of ongoing research and development leading to innovations as well as increasing demand from emerging countries.

Market Dynamics:

The global sleep aids market is driven by the rising prevalence of sleep disorders mainly due to changing dietary patterns, busy lifestyles, and increasing stress levels. Sleep deprivation is linked to numerous health issues like obesity, heart diseases, and depression which has boosted the adoption of sleep aids. The growing geriatric population which is more prone to sleep disorders also presents a large addressable market for industry players. However, side effects and risks associated with prescription sleep drugs pose a major challenge. Also, preference for alternative therapies in many countries hamper the market revenue growth to some extent. On the other hand, pace of innovation in sleep technology involving wearable devices and mobile apps offer new opportunities. Growing awareness about the consequences of insomnia and improving healthcare infrastructure in emerging nations will further support industry expansion going forward.

Key Features of the Study:

• This report provides an in-depth analysis of the global sleep aids market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global sleep aids market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this Pfizer Inc., GSK plc, Sommetrics, Inc., Cadwell Industries, Inc., SleepMed, Inc., Natus Medical Incorporated, Therapix Biosciences Ltd, Compumedics Limited, Eisai Co., Ltd., Tris Pharma, Inc., Novartis AG, Idorsia Pharmaceuticals Ltd., ResMed, AstraZeneca.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global sleep aids market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sleep aids market.

Detailed Segmentation-

• By Product Type:
  • Medications
  • Sleep Apnea Devices
  • Mattresses and Pillows
  • Others
• By Sleep Disorder:
  • Insomnia
  • Sleep Apnea
  • Restless Legs Syndrome
  • Night Terrors
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Pfizer Inc.
• GSK plc
• Sommetrics, Inc.
• Cadwell Industries, Inc.
• SleepMed, Inc.
• Natus Medical Incorporated
• Therapix Biosciences Ltd
• Compumedics Limited
• Eisai Co., Ltd.
• Tris Pharma, Inc.
• Novartis AG
• Idorsia Pharmaceuticals Ltd.
• ResMed
• AstraZeneca